引气三黄解毒汤治疗乙肝相关代偿期肝硬化:多中心随机对照试验方案
本研究为多中心随机对照试验方案,纳入5家医院802例乙肝相关代偿期肝硬化患者,随机分为引气三黄解毒汤(YQSHD)联合恩替卡韦(ETV)组与安慰剂联合ETV组,各401例。治疗52周、随访52±2周,主要结局为肝细胞癌年发病率,目标是将年发病率降至1%。
要点
- 中药联合抗病毒治疗可能降低乙肝相关代偿期肝硬化患者肝癌风险。
- 试验为多中心随机双盲安慰剂对照设计,样本量802例。
- 主要结局为肝细胞癌年发病率,目标降至1%。
核心结论
- 本试验旨在验证引气三黄解毒汤联合恩替卡韦能否降低乙肝相关代偿期肝硬化患者的肝细胞癌年发病率。
研究设计与样本
- 多中心随机对照试验,共纳入5家医院802例患者,随机分为YQSHD组(n=401)和安慰剂组(n=401)。
- YQSHD组接受YQSHD颗粒联合恩替卡韦,安慰剂组接受YQSHD安慰剂联合恩替卡韦。
- 治疗期52周,随访期52±2周,主要结局为肝细胞癌年发病率。
关键数值与推荐
- 主要结局指标为肝细胞癌年发病率,试验目标为联合治疗将年发病率降至1%。
- 治疗方案:YQSHD颗粒或安慰剂联合恩替卡韦,治疗52周。
临床怎么用
- 若试验达到目标,可为乙肝相关代偿期肝硬化患者提供中药联合抗病毒以降低肝癌风险的循证依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Hepatitis B-related compensated liver cirrhosis is related to a higher risk of hepatocellular carcinoma, and antiviral therapy is the preferred method. As the pathological mechanisms of liver fibrosis are complex, drugs developed for a single target are difficult to be effective in clinical practice, so there are no chemical drugs or biological drugs with clear efficacy available for clinical application at present. Traditional Chinese medicine is a kind of medical science that has been gradually formed during thousands of years and continuously enriched by the people of all ethnic groups in China. Traditional Chinese medicine shows curative effects in the treatment of liver diseases, especially in the field of liver fibrosis prevention and treatment. This study aims to test the integrative medicine (Chinese medicine plus antiviral therapy) effective on lowing hepatocellular carcinoma risk among patients with hepatitis-related compensated liver cirrhosis. METHODS AND ANALYSIS: This is a multi-center randomized controlled trial, and a total of 5 hospitals and 802 patients will be involved in. All the subjects are randomly allocated to the YinQiSanHuang Jiedu decoction (YQSHD) group (n = 401) or the placebo group (n = 401). The YQSHD group receives YQSHD granule with entecavir (ETV), and the placebo group receives YQSHD placebo with ETV. The treatment period will last for 52 weeks, and the follow-up period for 52 ± 2 weeks. The primary outcome measure is the annual incidence of HCC. Outcomes will be assessed at baseline and after treatment. The objective of this trial is "the integrative of YQSHD with ETV reduce the annual incidence of HCC to 1%." ETHICS AND DISSEMINATION: The protocol has been approved by the Medical Ethics Committee of Guang'anmen Hospital, China (No.2019-006-KY), and the other centers in the trial will not begin recruiting until the local ethical approval has been obtained. Trial final results will be disseminated via publication. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR1900021532 . Registered on February 26, 2019.
引用
- Wu QJ, Lv WL, Li JM, et al. YinQiSanHuang Jiedu decoction for the treatment of hepatitis B-related compensated liver cirrhosis: study protocol for a multi-center randomized controlled trial. Trials. 2021. PMID: 34649610. doi:10.1186/s13063-021-05650-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。